- Change in NCCN Guidelines regarding AR-V7 testing highlights significant advances in understanding the role of AR-V7 as a biomarker of resistance to androgen receptor (AR)-targeted therapies like abiraterone and enzalutamide
- The recommendation to consider AR-V7 testing to help guide selection of therapy is Category 2A for mCRPC patients
- Oncotype DX AR-V7 Nucleus Detect test is the only assay proven to detect resistance to AR-targeted therapies with near-absolute specificity2,3
Oncotype DX AR-V7 Nucleus Detect assay is the first and only liquid biopsy test that detects the AR-V7 protein variant in circulating tumor cells
Confidently select your next treatment option for mCRPC patients who have already received and failed an AR-targeted therapy
*Pages 26 and 27 of NCCN Guidelines 2.2019
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.2.2019. ©National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed [April17, 2019]. To view the most recent and complete version of the guideline, go online to NCCN.org.
- Scher et al. JAMA Oncol. 2016.
- Scher et al. JAMA Oncol. 2018